EIK 1005
Alternative Names: EIK-1005Latest Information Update: 24 Apr 2026
At a glance
- Originator Eikon Therapeutics
- Class Antineoplastics
- Mechanism of Action Werner syndrome helicase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 30 Mar 2026 Eikon Therapeutics initiates enrolment in a Healthy volunteer trial prior to March 2026
- 22 Jan 2026 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in Australia (unspecified route) (NCT07262619)
- 22 Jan 2026 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in Australia (unspecified route) (NCT07262619)